Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Minerva Neurosciences, Inc - Common Stock (NQ:NERV)

4.860 +0.500 (+11.47%)
Streaming Delayed Price Updated: 1:22 PM EDT, May 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Minerva Neurosciences, Inc - Common Stock

< Previous 1 2 Next >
News headline image
Minerva Neurosciences to Participate in the 2026 Jefferies Global Healthcare Conference
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Provides First Quarter 2026 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Announces Leadership Transition
Jim O’Connor joins as Chief Business Officer and General Counsel 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces First Patient Screened in Global Phase 3 Confirmatory Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
Minerva Neurosciences Inc. (NASDAQ: NERV) Near the Top of Equities by Percentage Gain on 6/28
Via Investor Brand Network
Minerva Neurosciences Inc. (NASDAQ: NERV) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
News headline image
Minerva Neurosciences Presents Data from its Open-label Safety Trial Evaluating Roluperidone Co-administered with Olanzapine at SIRS 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Participate in The Stifel 2026 Virtual CNS Forum
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Business Updates
Initiation of confirmatory Phase 3 trial with roluperidone for negative symptoms of schizophrenia is planned for Q2 2026, with topline data anticipated in 2H 2027 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Participate in The Citizens Life Sciences Conference
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Host Virtual KOL Event to Discuss Roluperidone: From Unmet Need to Reality – Potentially the First Treatment for Patients with Negative Symptoms of Schizophrenia, on February 3, 2026
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Appoints Dr. Inderjit Kaul to the Company’s Board of Directors
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces Financing of up to $200 Million to Advance Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia Through a Phase 3 Confirmatory Trial and Resubmission of its New Drug Application and Preparation
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Provides Business Updates and Second Quarter Financial Results
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports First Quarter 2025 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Company to host conference call today at 8:30 a.m. ET 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences to Report First Quarter 2023 Financial Results and Business Updates on May 15, 2023
Management to Host Conference Call 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
FDA grants appeal and files NDA 
From Minerva Neurosciences, Inc
Via GlobeNewswire
News headline image
Minerva Neurosciences Reports Fiscal Year 2022 Fourth Quarter And Year End Financial Results And Business Updates
Company to Host Conference Call Today at 8:30 a.m. ET 
From Minerva Neurosciences, Inc
Via GlobeNewswire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.